M25-709: A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Mirvetuximab Soravtansine in Subjects with Ovarian Cancer (FLORENZA)
- Title
- A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Mirvetuximab Soravtansine in Subjects with Ovarian Cancer (FLORENZA)
- Principal Investigator
- Pfaendler, Krista
- Phase
- II
- Age Group
- Adult
- Applicable Disease Sites
- Gynecologic Cancers
- Participating Institutions
- Mary Babb Randolph Cancer Center
- Contacts
- Jill Stone, LPN
- Research Specialist
- Phone: +1 304-634-4417
- Email: jill.stone@hsc.wvu.edu